Showing results (1-10 of 1,108) with videos related to
Sort By:
Pageof 111
Drugs|June 5, 2019
Recent Developments in LRRK2-Targeted Therapy for Parkinson's DiseaseYe Zhao, Nicolas DzamkoThe Biochemical Journal|May 29, 2025
Leucine-rich repeat kinase 2 biomarkers for Parkinson's diseaseNicolas DzamkoCNS Drugs|February 17, 2026
Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying TherapiesNicolas DzamkoNeurobiology of Disease|August 18, 2020
LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutationYe Zhao, Shikara Keshiya, Gayathri Perera, et al.Clinical Pharmacology : Advances and Applications|November 2, 2016
LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesFarzaneh Atashrazm, Nicolas DzamkoFrontiers in Neuroscience|March 27, 2020
Leucine Rich Repeat Kinase 2 and Innate ImmunityDiba Ahmadi Rastegar, Nicolas DzamkoBiochemical Society Transactions|September 20, 2012
An emerging role for LRRK2 in the immune systemNicolas Dzamko, Glenda M HallidayBiomolecules|November 11, 2022
LRRK2 and Lipid Pathways: Implications for Parkinson's DiseaseJasmin Galper, Woojin S Kim, Nicolas DzamkoNeurobiology of Disease|September 9, 2018
Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin miceYe Zhao, Shikara Keshiya, Farzaneh Atashrazm, et al.Pageof 111